On November 14, 2026 Servier reported updated four-year results from the Phase 2 FIREFLY-1 study of OJEMDA (tovorafenib) in patients aged six months to 25 years with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). The data are being presented as an oral presentation at the 31st Society for Neuro-Oncology (SNO) Annual Meeting on November 14 at 3:45 p.m. EST in Philadelphia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The four-year FIREFLY-1 analysis includes exploratory outcomes across the treatment and post-treatment observation periods, with a median study duration of 52.5 months in the registrational arm as of the June 5, 2026, data cutoff. Patients received OJEMDA orally once weekly in 28-day cycles for 26 cycles, after which they could continue treatment or enter the optional post-treatment observation period. The analysis assessed exploratory endpoints of time to next treatment and treatment-free interval to further characterize outcomes following treatment discontinuation.
"With four years of follow-up from FIREFLY-1, we are building a more complete picture of OJEMDA’s long-term outcomes, which will help physicians and families make critical treatment decisions," said Elly Barry, MD, Vice President of Clinical Development, Servier Pharmaceuticals. "We are proud to share these results, which, combined with the consistent safety profile, reinforce OJEMDA’s role as a meaningful treatment option. We remain committed to evaluating the effects of OJEMDA over time and continuing to support children, adolescents and young adults with pLGG."
Updated 4-year results from the phase 2 FIREFLY-1 study: Deep responses and prolonged time off therapy with tovorafenib in relapsed/refractory pediatric low-grade glioma – Saturday, November 14, 3:45 – 3:52 p.m. EST
Key findings from the exploratory analysis to be presented by Daniel Landi, MD, Duke University and Duke Cancer Institute, an investigator on the FIREFLY-1 trial, include:
Among the 76 efficacy-evaluable patients, median time to next treatment was 50.9 months (95% CI 36.7-not estimable [NE]).
The median time to next treatment in the three-year analysis, which was presented at SNO 2025, was 42.6 months.
Among the 41 patients who entered the optional post-treatment observation period:
76% of patients (n=31) remained treatment-free for at least 12 months, and 54% of patients (n=22) remained treatment-free for at least 24 months. The median treatment-free interval was not reached.
54% of patients (n=22) experienced tumor rebound off treatment and seven patients were retreated.
27% of patients (n=11) were retreated with OJEMDA. At last scan, nine of those patients had a smaller tumor than prior to retreatment.
Five of 13 patients with BRAF V600E mutations experienced tumor rebound and four were retreated.
The safety profile of OJEMDA remained consistent with the established profile. In the safety analysis set (n=137), the most common Grade ≥3 treatment-related adverse events (TRAEs) observed in ≥5% of patients included reduced growth velocity (36%), anemia (14%), increased CPK (11%), maculopapular rash (8%), and increased ALT (5%). There were no treatment-related deaths and no additional discontinuations due to TRAEs since the three-year data cutoff.
In the growth analysis set (n=90), 88% of patients (n=79) demonstrated growth recovery, irrespective of the degree of on-treatment growth suppression.
"For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful," said Daniel Landi, MD, Duke University and Duke Cancer Institute. "These longer-term FIREFLY-1 findings provide additional information about patient outcomes, including treatment duration and time off therapy, which may help inform discussions between physicians and families about treatment decisions."
Media Contact
Darby Malkin: [email protected]
About OJEMDA
OJEMDA (tovorafenib) is a Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Tovorafenib was granted Breakthrough Therapy and Rare Pediatric Disease designations by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration, and it was evaluated by the FDA under priority review. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma and from the European Commission for the treatment of glioma.
Please see full prescribing information including important safety information about OJEMDA at www.OJEMDA.com.
About Pediatric Low-Grade Glioma
Pediatric low-grade gliomas (pLGG) are the most common brain tumor with an estimated US incidence of 1,100 and Europe incidence of 700 children per year who are eligible for front-line systemic therapy.1,2 BRAF is the gene most commonly altered in pLGG, which includes two primary types of BRAF alterations – a BRAF gene fusion and BRAF point mutation. These BRAF alterations account for >50% of pLGG cases worldwide and prior to the introduction of OJEMDA, there were no approved treatments for people with pLGG driven by BRAF fusions.1,3
Pediatric low-grade gliomas can be chronic and relentless, with patients suffering profound side effects from both the tumor and the treatment, which may include chemotherapy and radiation. These side effects can impact their life over the long term, and may include motor deficiencies, vision loss, hormone deficiency and alterations in growth and development. Most children with pLGG will survive their cancer, but for the majority of those in whom a complete surgical resection is not possible, these tumors tend to recur frequently throughout childhood, necessitating multiple treatments. The cumulative toxicity of numerous therapies, along with the damage caused by multiple episodes of tumor progression, take a significant toll on the children and their families.
(Press release, Servier, NOV 14, 2026, View Source [SID1234674779])